fda semaglutide obesity A big win for Wegovy: Weight loss drug first in history to gain approval for reducing heart risks What BMI Do You Need

Potential side effects

Brand note: Ozempic is a trademark of Novo Nordisk A/S, not affiliated with Omzo

In February 2026, full results from the REDEFINE 2 study showed CagriSema achieving 23% weight loss at 84 weeks but falling short of its primary endpoint under the treatment policy estimand (which measures efficacy across all patients regardless of whether they completed treatment, rather than only those who remained on it)

It guarantees that the peptides your patients receive are accurately dosed, pure, and safe for administration, maintaining the high standards of care expected in a clinical setting

Grasping the wider impact of retatrutide may influence the evolution of obesity treatment

In pregnancy, choline deficiency increases the risk of neural tube defects and affects brain development in the baby.[ref] What do the different types of choline do in the body